Brief: UCB Announces Positive Results From Gemz Phase 3 Study Of Fenfluramine In Cdkl5 Deficiency Disorder
27/06/2025 12:15
June 27 (Reuters) - Ucb SA UCB.BR: UCB ANNOUNCES POSITIVE RESULTS FROM GEMZ PHASE 3 STUDY OF FENFLURAMINE IN CDKL5 DEFICIENCY DISORDER Source text: ID:nPn4SMNl6a Further company coverage: UCB.BR ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside